PRTC News and Press, PureTech Health plc From 06/29/21

Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences , a leading clinical-stage ...

Karuna to initiate a Phase 2 trial evaluating KarXT in dementia-related psychosis in the first half of 2022 Results suggest that KarXT can be administered to elderly volunteers at doses which achieve xanomeline blood levels similar to those reported in the Phase 2 EMERGENT-1 t...

Oral IL-22 and other preclinical therapeutic candidates as well as the underlying technology platform to be integrated in the Company’s Wholly Owned Pipeline PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a...

The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Thursday, May 27, 2021. All of the resolutions proposed at the Annual General Meeting were duly passed by th...

Analysis showed that treatment for weight management with Plenity resulted in NALFD Fibrosis Score Improvement These data support further clinical investigation using Gelesis’ superabsorbent hydrogel platform for the potential treatment of metabolic-related live...

Funding expected to accelerate commercialization of Akili’s flagship treatment, EndeavorRx™, enable expansion of core technologies to treat acute and chronic cognitive disorders, and drive further research and development of new digital therapeutics PureTech ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that D...

PureTech Health (PRTC) announces the formation of its clinical advisory board for idiopathic pulmonary fibrosis ((IPF)) and other progressive fibrosing interstitial lung diseases ((PF-ILDs)).The advisory group will work closely with the company in the advancement of its anti-fibroti...

Leading experts in the field will advise on clinical development of PureTech’s lead, wholly-owned product candidate, LYT-100, in idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases PureTech Health plc (Nasdaq: PRTC, LSE: PR...

Preclinical research suggests that restoring lymphatic flow in the brain has the potential to address a range of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases, and associated neuroinflammation Additionally, research found that improving...